CompletedPhase 1 / Phase 2NCT03568656
Official study titleStudy to Evaluate CCS1477 in Advanced Tumours
Study summary
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours.
Ask AI to explain this studyStart here
Key things to know
Main goalTreatment
This describes the study’s primary purpose.
What is being studiedCCS1477 and Abiraterone acetate
Plus 4 other study approaches.
Who it may be forNon-small cell lung cancer (NSCLC) · Metastatic or stage IV
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Sep 25, 2026 · Source: ClinicalTrials.gov
Is enrollment open?Completed
Ask the study team to confirm whether enrollment is open.
What kind of study?Phase 1 / Phase 2
Interventional
Where is it offered?19 U.S. locations
Locations may change over time.
Who runs it?CellCentric Ltd.
Study sponsor
Study overview
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- CellCentric Ltd.
- Interventions being studied
- Drug: CCS1477; Drug: Abiraterone acetate; Drug: Enzalutamide; Drug: Darolutamide; Drug: Olaparib; Drug: Atezolizumab
Explore related studies
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Cancer type
Disease setting
Treatment approach
Public criteria
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
Requirements people may need to meetInclusion criteria
- Provision of consent
- ECOG performance status 0-1
- Assessable disease (by CT, MRI, bone scan or X-ray)
- Adequate organ function
- Highly effective contraception measures for duration of study Additional inclusion criteria for mCRPC patients only:
- Previously received abiraterone and/or enzalutamide (or equivalent anti-androgen), and docetaxel (unless ineligible or refused)
- Progressive disease documented by one or more of the following:
- Biochemical progression defined as at least 2 stepwise increases in a series of any 3 PSA values
- Progression as defined by RECIST v1.1 guideline for assessment of malignant soft tissue disease.
- Progression defined as two or more new metastatic bone lesions confirmed on bone scan from a previous assessment
- PSA at screening ≥2 μg/L
- Serum testosterone concentration ≤50 ng/dL
- Serum albumin \>2.5 g/dL Additional inclusion criteria for patients in CCS1477 plus abiraterone combination arm:
- Patients must have previously progressed on abiraterone treatment
- Patients whose last dose of abiraterone is greater than 6 months prior to start of study treatment will receive a 4-week run-in treatment with abiraterone to confirm refractoriness to abiraterone treatment Additional inclusion criteria for patients in CCS1477 plus enzalutamide combination arm:
- Patients must have previously progressed on enzalutamide treatment
- Patients whose last dose of enzalutamide is greater than 6 months prior to start of study treatment will receive a 4-week run-in treatment with enzalutamide to confirm refractoriness to enzalutamide treatment Additional inclusion criteria for patients in mutation arm:
- Advanced solid tumour with identification of markers which may indicate potential for response to p300/CBP inhibition. Markers include loss of function mutations in CREBBP, EP300 or ARID1A, MYC gene amplifications or rearrangements and androgen receptor (AR) gene amplifications or over-expression.
Reasons someone may not be able to joinExclusion criteria
- Intervention with any chemotherapy, investigational agents or other anti-cancer drugs within 14 days or 5 half-lives of the first dose
- Radiotherapy with a wide field of radiation or to more than 30% of the bone marrow within 4 weeks of the first dose of study treatment
- Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study treatment
- Strong inhibitors of CYP3A4 or CYP3A4 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment
- Strong inducers of CYP3A4 within 4 weeks of the first dose of study treatment
- Statins; patients should discontinue statins prior to starting study treatment
- Any unresolved reversible toxicities from prior therapy \>CTCAE grade 1 at the time of starting study treatment
- Any evidence of severe or uncontrolled systemic diseases
- Any known uncontrolled inter-current illness
- QTcF prolongation (\> 480 msec).
- Primary brain tumours or known or suspected brain metastases. Additional
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
Study sites
U.S. locations
- Dana-Farber Cancer InstituteBoston, Massachusetts
- Thomas Jefferson University, Sidney Kimmel Cancer CenterPhiladelphia, Pennsylvania
- Institute BergonieBordeaux
- Hôpital Europeen Georges PompidouParis
- Institute Gustave RoussyVillejuif
- Netherlands Cancer Institute (NKI)Amsterdam
- Hospital Vall d'Hebron, VHIOBarcelona
- START CIOCC Hospital Universitario HMMadrid
- Karolinska InstituteStockholm
- Belfast City HospitalBelfast
- Queen Elizabeth Hospital Cancer CentreBirmingham
- Cambridge University HospitalCambridge
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 25, 2026. Always confirm current availability with the study team.